Why NAD+ Declines With Age: The 3 Mechanisms Affecting Cellular Energy
NAD+ decline is not a side effect of ageing. It is one of the primary drivers of ageing itself.
By the time you reach 60, your cells contain roughly half the NAD+ they held at 20. That loss is not random. Three specific biological processes consume and suppress NAD+ in a coordinated, compounding way as the years pass.
Understanding them explains why energy falters, DNA repair slows, and cellular function degrades in middle age — and why restoring NAD+ through its most direct precursor, nicotinamide mononucleotide, is increasingly studied as a longevity intervention.
What NAD+ Actually Does in Your Cells
Nicotinamide adenine dinucleotide functions as both a coenzyme and a signalling molecule. In its oxidised form, NAD+ accepts electrons during glucose metabolism, shuttling them to the mitochondrial electron transport chain where ATP is synthesised. Without adequate NAD+, that process stalls.
Beyond energy metabolism, NAD+ is the required substrate for two enzyme families that are central to ageing biology:
| Enzyme family | Primary role | What happens when NAD+ falls |
|---|---|---|
| Sirtuins (SIRT1, SIRT3, SIRT6) | Gene expression, mitochondrial biogenesis, inflammation regulation | Activity drops, ageing accelerates across multiple systems |
| PARPs (especially PARP1) | DNA strand break detection and repair | Repair slows, mutations accumulate over time |
Both families consume NAD+ in the course of their activity. Every DNA repair event and every sirtuin activation cycle draws from the same pool.
When NAD+ falls, these systems do not fail gradually. They fail competitively. Whichever process most urgently needs NAD+ wins, and the others are rationed.
Mat Stuckey, founder of Longevity Formulas: "When I first read about the PARP1-sirtuin competition for NAD+, it reframed everything I thought I knew about why we age. It is not just wear and tear. It is a resource war happening inside every cell — and the resource is something we can actually influence. That realisation is what led me to build this brand."
The Three Mechanisms Behind NAD+ Decline
Mechanism 1: CD38 Overexpression
CD38 is a glycohydrolase enzyme whose primary function is to cleave NAD+ into nicotinamide and ADP-ribose as part of calcium signalling. In young tissue, CD38 activity is moderate and tightly regulated.
With age, chronic low-grade inflammation — what researchers now call inflammageing — triggers the immune system to produce more inflammatory cells. These cells express high levels of CD38. The result is a progressive increase in NAD+ consumption that is entirely unrelated to energy production or DNA repair. CD38 in aged tissue is estimated to consume the majority of NAD+ that would otherwise be available to sirtuins and PARPs.
What the research shows: CD38 expression in aged mouse tissue was found to be 2.6-fold higher than in young tissue. CD38 knockout mice maintained youthful NAD+ levels well into old age, confirming that CD38 overexpression is causal, not incidental, in the NAD+ decline story.
The practical implication is significant. Restoring NAD+ by supplementing precursors addresses the supply side, but the drain imposed by CD38 continues unless the underlying inflammatory environment is also managed. This is one reason researchers study NMN alongside anti-inflammatory compounds such as resveratrol, which activates SIRT1 — a sirtuin that itself exerts anti-inflammatory effects.
The Longevity Formulas team: "This is why we formulated our NMN Complex with resveratrol and TMG rather than selling NMN alone. Addressing just the NAD+ supply while ignoring the inflammatory drain felt like filling a leaking bucket. The combination makes more physiological sense, and it is what we take ourselves."
Mechanism 2: PARP1 Hyperactivation Under DNA Stress
PARP1 is the most active of the PARP enzyme family. Its job is to detect single and double-strand breaks in DNA and initiate repair by synthesising poly-ADP-ribose chains at the damage site. Each chain extension consumes NAD+.
In young cells, DNA damage is relatively infrequent and repair events are efficient. With age, three things change simultaneously:
- Oxidative stress increases as mitochondrial efficiency declines, generating more reactive oxygen species that damage DNA
- Telomere shortening creates persistent DNA damage signals that keep PARP1 partially activated even between repair events
- Accumulated mitochondrial DNA mutations generate additional chronic stress signals
The result is chronic PARP1 activation — an enzyme running continuously rather than episodically. Each repair cycle consumes NAD+. Each molecule consumed by PARP1 is one less available to sirtuins. Since SIRT1 and SIRT3 require NAD+ to function, their activity falls in direct proportion to PARP1's overconsumption.
This is the competition at the heart of the ageing NAD+ crisis.
Mat Stuckey: "I started taking NMN at 38, partly for energy but mostly because I'd read enough about DNA repair to understand that the window where supplementation makes a meaningful difference is probably earlier than most people think. By the time you can feel the deficit, it has been building for years. I did not want to wait."
Studies in aged rodents have shown that partial PARP1 inhibition restores sirtuin activity and extends healthspan — not because PARP1 is harmful, but because the balance between DNA repair and metabolic regulation had been disrupted. The preferred clinical approach is to restore NAD+ supply rather than inhibit PARP1, since DNA repair must not be compromised. NMN supplementation expands the total NAD+ pool available to both enzyme families simultaneously.
Mechanism 3: NAMPT Suppression and the Salvage Pathway Bottleneck
The salvage pathway is the primary route by which cells recycle nicotinamide — a byproduct of NAD+ consumption — back into usable NAD+. The rate-limiting enzyme in this pathway is NAMPT, nicotinamide phosphoribosyltransferase.
NAMPT converts nicotinamide into NMN, which is then converted to NAD+ by NMNAT enzymes. In healthy young tissue, NAMPT activity is sufficient to maintain NAD+ levels despite ongoing consumption by PARPs and sirtuins.
Why NAMPT declines with age:
- Epigenetic silencing of the NAMPT gene reduces baseline expression
- Reduced SIRT1 activity lowers NAMPT transcription (SIRT1 upregulates NAMPT in a feedback loop, so when SIRT1 falls, NAMPT follows)
- Oxidative damage impairs the enzyme's activity directly
When NAMPT falls, the salvage pathway slows. Cells become dependent on dietary precursor intake to maintain NAD+ levels — intake that for most people is inadequate to compensate for the shortfall.
The downstream consequence of this depletion is visible in two places above all others: the mitochondria lose the NAD+ they need to run the electron transport chain efficiently, which is covered in detail in our guide to NMN and mitochondrial function, and the DNA repair enzyme PARP1 begins competing with sirtuins for what little NAD+ remains — a process explained fully in our piece on how NAD+ powers your DNA repair system.
Why NMN bypasses this bottleneck: NMN enters the biosynthetic pathway downstream of NAMPT, converting directly to NAD+ via NMNAT enzymes without requiring the rate-limiting step. This is mechanistically why NMN tends to raise blood NAD+ levels more efficiently than niacin or nicotinamide alone — both of which still require the NAMPT conversion to complete.
How All Three Mechanisms Compound Each Other
These three mechanisms do not operate independently. They form a feedback loop that accelerates with age.
The compounding cycle:
- Inflammageing raises CD38 expression, which depletes NAD+
- Reduced NAD+ impairs SIRT1 activity
- Reduced SIRT1 lowers NAMPT transcription, slowing the salvage pathway
- Declining mitochondrial function from reduced NAD+ generates more ROS
- More ROS means more DNA damage and more PARP1 activation
- More PARP1 activation drains NAD+ further
- Return to step 1, faster
This is why NAD+ decline accelerates non-linearly from the mid-40s onward, and why the impact on energy, recovery, cognitive function, and metabolic health compounds over time rather than declining at a steady rate.
Mat Stuckey: "The feedback loop is the single thing I wish I had understood ten years earlier. It makes clear that this is not one problem with one fix. It is a system. You have to address the supply, reduce the inflammatory drain, and support the recycling pathway together. That thinking guided every formulation decision we made at Longevity Formulas."
NAD+ Decline by Decade
| Age range | Approximate NAD+ vs age 20 | Key drivers active |
|---|---|---|
| 20s | 100% | Baseline — NAMPT active, CD38 low, oxidative stress low |
| 30s | ~85% | NAMPT begins declining, mild CD38 increase |
| 40s | ~65% | PARP1 demand rising, inflammageing establishing |
| 50s | ~50% | All three mechanisms compounding significantly |
| 60s+ | ~40–45% | Substantial deficit across all NAD+-dependent systems |
Approximate figures based on tissue NAD+ measurements in published ageing research. Individual variation applies.
What Restoring NAD+ Precursors Can Do
Human clinical trials have demonstrated that oral NMN supplementation reliably raises blood NAD+ levels. A 2022 study in NPJ Aging found that 250mg of NMN daily for 12 weeks significantly increased NAD+ concentrations in peripheral blood mononuclear cells. A Keio University trial showed that 500mg daily was safe and well-tolerated in healthy adults, with no serious adverse events recorded.
The practical effects observed across trials include improvements in muscle function, insulin sensitivity, energy levels, and sleep quality — outcomes consistent with restoring substrate availability to NAD+-dependent systems across multiple tissue types.
For support across the interconnected systems involved in cellular energy and NAD+ metabolism, our NAD+ boosting supplements range includes NMN in multiple formats alongside the complementary compounds most studied in these pathways.
For a complete overview of how NMN works once NAD+ levels are restored, see our NMN Guide.
Reviewed by the Longevity Formulas team. Referenced studies are catalogued on our clinical research on NMN page.
